The Bcl-2 gene is a negative regulator of cellular apoptosis that displays heightened expression in a wide range of cancers. Increased levels of this and other apoptotic suppressors (e.g ...

The proto-oncogene bcl-2 is known as an anti-apoptotic gene that confers the ability to block neuronal cell death after transient ischemia. In order to examine whether the bcl-2 gene can be used ...

Chemotherapy might or might not work depending on the composition of the Bcl-2 gene family. Any cancer drug targeting those genes could prove far more successful than is the case now.

The tumor-suppressor gene TP53 and the proto-oncogene bcl-2 encode, respectively, for a nuclear phosphoprotein and for a mitochondrial protein involved in multiple cellular functions. The proteins ...

bcl-2 Gene rearrangement; Molecular Test Detection bcl-2 Gene rearrangement Written by Dr. Reeja Tharu, M.Phil.,Ph.D. Medically Reviewed by Dr. Simi Paknikar, MD. Last Updated on Sep 22, 2014.

The gene encoding B-cell lymphoma-2 (BCL-2) is highly expressed in many hematological malignancies, making it a promising target. Two abstracts presented at the 64th American Society of Hematology ...

The BCL-2 inhibitors market is anticipated to experience substantial growth in the upcoming years. This growth is driven by a rising number of cancer diagnoses, heightened awareness of BCL-2 ...

ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in ...

Bcl-3 gene is involved in T cell survival. Immunological adjuvants may improve survival of activated T cells via induction of the Bcl-3 gene. Tudor Toma. Tudor Toma. This person does not yet have a ...

The t(14;18) translocation involving the bcl-2 gene and the amplification of the c-rel locus on chromosome 2p occurred exclusively in germinal-center B-cell–like diffuse large-B-cell lymphomas .

At the time of the deal, Fosun hyped up BCL-2 as an “increasingly important therapeutic target in cancer biology.” Lilly presumably agreed, handing over $40 million and pledging up to $400 ...